TPTX
Turning Point Therapeutics, Inc.
A San Diego biopharmaceutical company developing precision cancer medicines called kinase inhibitors that target specific gene mutations fueling tumor growth. Its lead experimental drug, repotrectinib, was designed for patients with ROS1- and TRK-driven cancers, including non-small cell lung cancer. Founded in 2013, the company was acquired by Bristol Myers Squibb in 2022; the name reflects its goal of marking a turning point in treatment for hard-to-treat cancers.
CUSIP: 90041T108HealthcareUS1 holder
Recent Activity
2021Q1
1 sell
-40.0K shares
-40.0K shares
Loading more activity...